IE40794L - Influenza vaccine. - Google Patents
Influenza vaccine.Info
- Publication number
- IE40794L IE40794L IE750059A IE5975A IE40794L IE 40794 L IE40794 L IE 40794L IE 750059 A IE750059 A IE 750059A IE 5975 A IE5975 A IE 5975A IE 40794 L IE40794 L IE 40794L
- Authority
- IE
- Ireland
- Prior art keywords
- influenza
- components
- virus
- type
- cationic detergent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Detergent Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
1498261 Influenza vaccines SANDOZ Ltd 13 Jan 1975 [14 Jan 1974] 1290/75 Heading A5B The haemagglutinin and neuramuridase components are isolated from influenza virus by treating the virus in an aqueous medium with a cationic detergent to selectively solubilise such components, and separating the resulting solubilised such components from residual sub-viral particles. The virus concentrate may have a pH of from 6.5 to 8.5 and may inactivated with formaldehyde prior to the addition of the cationic detergent. After addition of the cationic detergent, the resulting mixture is preferably allowed to stand for 30 minutes to 16 hours at 4‹C to 37‹C. Influenza vaccines comprise a mixture of the haemagglutinin and neuramuridase components of an influenza virus, in the substantial absence of other components of the influenza viral particle in association with -an inertliquid diluent such as physiological saline optionally phosphate buffered. The vaccine may additionally comprise a preserving or inactivating agent such as formaldehyde and/or an immunological adjuvant such as aluminium hydroxide or aluminium phosphate. The influenza virus may be an influenza Type A, A 1 , A 2 or B virus, strain A2/Aichi/68, MRC-2 (recombination of Type A2/England/42/72), MRC-11 (recombination of Type A2/Port Chalmers/73), A/Pasteur/30C (Mutagrip), or B/Mass/67.
[GB1498261A]
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH44774A CH589453A5 (en) | 1974-01-14 | 1974-01-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE40794L true IE40794L (en) | 1975-07-14 |
| IE40794B1 IE40794B1 (en) | 1979-08-15 |
Family
ID=4187233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE59/75A IE40794B1 (en) | 1974-01-14 | 1975-01-13 | Influenza vaccines |
Country Status (27)
| Country | Link |
|---|---|
| JP (2) | JPS58407B2 (en) |
| AT (1) | AT345449B (en) |
| AU (1) | AU500250B2 (en) |
| BE (1) | BE824372A (en) |
| CA (1) | CA1049406A (en) |
| CH (1) | CH589453A5 (en) |
| CS (1) | CS191254B2 (en) |
| DD (1) | DD116239A5 (en) |
| DE (1) | DE2500785B2 (en) |
| DK (1) | DK140003B (en) |
| ES (1) | ES433759A1 (en) |
| FI (1) | FI54053C (en) |
| FR (1) | FR2257305B1 (en) |
| GB (1) | GB1498261A (en) |
| HK (1) | HK56380A (en) |
| HU (1) | HU173920B (en) |
| IE (1) | IE40794B1 (en) |
| IL (1) | IL46426A (en) |
| MY (1) | MY8100204A (en) |
| NL (1) | NL166622C (en) |
| NO (1) | NO143128C (en) |
| PH (1) | PH14458A (en) |
| PL (1) | PL93689B1 (en) |
| SE (1) | SE427238B (en) |
| SU (1) | SU616997A3 (en) |
| YU (1) | YU41289B (en) |
| ZA (1) | ZA75259B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2829089A1 (en) * | 1977-07-13 | 1979-02-01 | Sandoz Ag | SUBUNIT VACCINE |
| JPH0688911B2 (en) * | 1985-06-06 | 1994-11-09 | 国立予防衛生研究所長 | Influenza vaccine and method for producing the same |
| TW570803B (en) * | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
| EP0919243A1 (en) | 1997-11-25 | 1999-06-02 | Duphar International Research B.V | Vaccine containing B subunits of heat-labile enterotoxin (LTB) of Escherichia coli as an adjuvant |
| DE19938767C2 (en) * | 1999-08-16 | 2002-10-24 | Tad Pharma Gmbh | subunit vaccines |
| WO2007052163A2 (en) * | 2005-11-01 | 2007-05-10 | Novartis Vaccines And Diagnostics Gmbh & Co Kg | Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment |
| SG10201404101RA (en) * | 2007-08-28 | 2014-09-26 | Baxter Int | Method For Producing Viral Vaccines |
| AU2014350370B2 (en) | 2013-11-15 | 2017-04-13 | Novartis Ag | Removal of residual cell culture impurities |
-
1974
- 1974-01-14 CH CH44774A patent/CH589453A5/xx not_active IP Right Cessation
-
1975
- 1975-01-06 DK DK1475AA patent/DK140003B/en not_active IP Right Cessation
- 1975-01-06 NO NO750031A patent/NO143128C/en unknown
- 1975-01-06 FI FI750014A patent/FI54053C/en not_active IP Right Cessation
- 1975-01-07 SE SE7500130A patent/SE427238B/en not_active IP Right Cessation
- 1975-01-10 DE DE2500785A patent/DE2500785B2/en active Granted
- 1975-01-10 NL NL7500301.A patent/NL166622C/en not_active IP Right Cessation
- 1975-01-13 PH PH16702A patent/PH14458A/en unknown
- 1975-01-13 ES ES433759A patent/ES433759A1/en not_active Expired
- 1975-01-13 PL PL1975177303A patent/PL93689B1/pl unknown
- 1975-01-13 AT AT21475A patent/AT345449B/en not_active IP Right Cessation
- 1975-01-13 HU HU75SA2736A patent/HU173920B/en not_active IP Right Cessation
- 1975-01-13 IE IE59/75A patent/IE40794B1/en unknown
- 1975-01-13 GB GB1290/75A patent/GB1498261A/en not_active Expired
- 1975-01-13 CA CA217,790A patent/CA1049406A/en not_active Expired
- 1975-01-13 IL IL46426A patent/IL46426A/en unknown
- 1975-01-13 DD DD183614A patent/DD116239A5/xx unknown
- 1975-01-13 YU YU58/75A patent/YU41289B/en unknown
- 1975-01-14 ZA ZA00750259A patent/ZA75259B/en unknown
- 1975-01-14 CS CS75255A patent/CS191254B2/en unknown
- 1975-01-14 SU SU752101722A patent/SU616997A3/en active
- 1975-01-14 JP JP50006975A patent/JPS58407B2/en not_active Expired
- 1975-01-14 BE BE152368A patent/BE824372A/en not_active IP Right Cessation
- 1975-01-14 FR FR7501007A patent/FR2257305B1/fr not_active Expired
- 1975-01-14 AU AU77305/75A patent/AU500250B2/en not_active Expired
-
1980
- 1980-10-09 HK HK563/80A patent/HK56380A/en unknown
-
1981
- 1981-01-29 JP JP56012831A patent/JPS6035326B2/en not_active Expired
- 1981-12-30 MY MY204/81A patent/MY8100204A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Haslam et al. | The structural proteins of Newcastle disease virus | |
| CA2121241A1 (en) | Porcine reproductive respiratory syndrome vaccine and diagnostic | |
| IE40794B1 (en) | Influenza vaccines | |
| Lahelle et al. | Hemagglutination with the GDVII strain of mouse encephalomyelitis virus | |
| IE781880L (en) | Immunogenic herpes virus subunit | |
| Hirst et al. | A new method for concentrating influenza virus from allantoic fluid | |
| AU2004249802B2 (en) | Improvements in virus production | |
| IE40180B1 (en) | Influenza virus vaccines and preparation thereof | |
| IE870507L (en) | Bovine virus diarrhea and hog cholera vaccines | |
| Wilcox et al. | Soluble Antigens of Vaccinia-infected Mammalian Cells II. Time Course of Synthesis of Soluble Antigens and Virus Structural Proteins | |
| GB2001326A (en) | Glycoproteins from paramyxovirus and vaccines therefrom | |
| IE40221L (en) | Influenza vaccines | |
| GB1256457A (en) | Diethylaminoethyldextran (deae-d) as adjuvant for vaccines for active immunisation | |
| AU5573196A (en) | A pluripotent vaccine against enveloped viruses | |
| GB660109A (en) | Improvements in or relating to the treatment of allantoic fluid containing a propagated virus together with non-viral proteins to obtain the virus in purified and viable from for use in a vaccine | |
| GB1016586A (en) | Vaccine for immunization of dogs against distemper and hepatitis contagiosa canis | |
| IE830861L (en) | Equine influenza vaccine. | |
| ES8107024A1 (en) | Feline infectious peritonitis vaccine and process for its preparation. | |
| JP2841592B2 (en) | Virus particle disruption method | |
| GB1434181A (en) | Vaccine for the prevention and treatment of vascular conditions | |
| Greer et al. | Electron microscope study of the interaction of vaccinia virus with macrophages from immunized and nonimmunized rabbits | |
| GB777018A (en) | Poliomyelitis vaccine products and methods for preparing the same | |
| EP0374817A3 (en) | Method for disrupting virus particles | |
| 郭元吉 et al. | Influenza C virus isolated from pigs in China | |
| GB1481650A (en) | Chemical processes and products |